Actionable news
All posts from Actionable news
Actionable news in KITE: KITE PHARMA Inc,

Kite Cancer Therapy Responses in Solid Tumors Sustained in Trial

A cancer therapy licensed by Kite Pharma Inc. continued to be safe and show durable responses against solid tumors for some patients in an early-stage trial run by the U.S. National Cancer Institute.

In a trial of 14 patients who received different doses, three patients’ cancers have shrunk partially, according to a study presented Sunday at the American Association for Cancer Research’s conference in New Orleans. The researchers had presented initial positive data in November, and the updated study shows that the three partial responses were durable, with one cervical cancer patient’s response continuing at 15 months.

Genetically engineered T-cell therapies are an emerging form of cancer treatment in...